Alliance to drive greater efficiencies across clinical trials in oncology and hematology

BOSTON and OSAKA, August 21, 2017– PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Osaka International Cancer Institute today announced that they have formed an alliance to advance clinical development in Japan. The partnership will aim to drive greater efficiencies in support of patient recruitment for clinical trials in oncology and hematology, accelerating the development of innovative and effective new cancer treatments for patients.

“Oncology continues to be the largest therapeutic area in clinical trials today, and is a priority for PAREXEL as we partner with clients to deliver new therapies to patients in need,” said Shogo Nakamori, Corporate Vice President, Clinical Research Services, Asia Pacific, PAREXEL. “Osaka International Cancer Institute is a center of excellence for clinical trials in the Kansai region of Japan. Through this alliance, PAREXEL and the Osaka International Cancer Institute will work to drive greater efficiencies for local and global biopharmaceutical companies, helping them accelerate the clinical development of innovative and effective new treatments in this difficult disease area.”

Global artificial intelligence market expected to reach USD 35,870.0 million by 2025

August 17, 2017 – ( www.investorideas.comnewswire) Investorideas.com, a global news source covering leading sectors including technology releases its updated stock directory for Artificial Intelligence (AI) and Robotics  stocks.

Read this news in full at http://www.investorideas.com/news/2017/artificial-intelligence/08171StockDirectory.asp

According to a recent report published by Grand View Research, “The global artificial intelligence market is expected to reach USD 35,870.0 million by 2025 from its direct revenue sources, growing at a CAGR of 57.2% from 2017 to 2025, whereas it is expected to garner around USD 58,975.4 million by 2025 from its enabled revenue arenas.

August 15, 2017 – Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks issues an exclusive podcast interview with David Schrader, Chief Operating Officer at Scythian Biosciences Corp.  (TSX.V: SCYB).

Scythian Biosciences Corp. seeks to develop the first accepted drug regimen for concussion and traumatic brain injury with their cannabinoid-based combination drug therapy.

Read this news in full at http://www.investorideas.com/CO/SCYB/news/2017/08151Podcast.asp

“There is no currently accepted drug regimen for the treatment of traumatic brain injury and concussion,” said Scythian’s Chief Operating Officer, David Schrader.

Point Roberts, WA,- August 9, 2017 – Investorideas.com, a global news source covering leading sectors including bitcoin and cannabis stocks, releases an exclusive interview with WilRalston, of  SinglePoint Inc. (OTC: SING) .

Wil expands on the company’s recent news about its new Bitcoin exchange, and their goal of solving the issues in payments plaguing the cannabis industry. He also talks about the company’s background in both sectors and how much research has taken place to get to their beta launch at the Las Vegas Marijuana Business MJBIZCON November 14th - 17^th.

Read this news in full at http://www.investorideas.com/CO/SING/news/2017/08091WilRalston.asp

Watch the video:https://www.youtube.com/watch?v=PiqZ4YYL4AQ